An analysis published in JAMA finds that Medicare is wasting about a billion dollars a year purchasing brand-name drugs.
Read More
InquisitiHealth has asked for and received about $4 million in funding to create peer mentors to help people manage their health and wellness.
https://medcitynews.com/2018/08/inquisithealth-funding-population-health/?utm_campaign=MCN%20Daily%20Top%20Stories&utm_source=hs_email&utm_medium=email&utm_content=65369320&_hsenc=p2ANqtz-_ajETvdFk0mLm984JySRT1SyyuoHMbvis0BHzG84n4ooT4iKPcR_n31Anj02hSPljhDUzzGlgs3A37M6Zw1LF7rWotMnW2AbQJmSjjqNvaGSVaxv4&_hsmi=65369320&rf=1An analysis in Health Affairs compares hospital, home health and SNF use and variation in Medicare Advantage versus the fee-for-service version.
Read More
WellBrain is acquiring Mevoked, and investors will hopefully combine the names and get "Woked". WellBrain has apps to help with chronic pain management and Mevoked has apps to help women with pregnancy, a natural fit since the product of pregnancy often creates pain for the parents. Well, Brainy investors, Me has joked enough.
https://www.prnewswire.com/news-releases/wellbrain-founded-by-3-harvard-stanford-and-mayo-clinic-trained-physicians-expands-its-reach-as-one-of-the-largest-clinically-validated-digital-chronic-pain-management-and-addiction-prevention-tools-with-recent-mevoked-acquis-300697724.htmlA report from the Minnesota Department of Health reveals the variation in hospital pricing.
Read More
HealthMyne has secured $15 million in new capital for its clinical decision support system for radiology and oncology.
https://www.businesswire.com/news/home/20180801005016/en/HealthMyne-Raises-15-Million-Series-Expand-Commercialization?utm_medium=nl&utm_source=internal&mrkid=635530&mkt_tok=eyJpIjoiTkRNeU5EazJNbVF5T0RZMiIsInQiOiJQNEk2ZmFsRGlWOFhJdDlBOXRHUUFDN0xnUlJwTThhMHFNUXN3NlM3MFVsRTBHUkVTcWhlZXU1MjVMU2FhUWZuYlptbEtyRFwvNkdnS1FESmVWYWdSMEc1VUpha1Y2aFhwWFRhbldMQlNJQXFNaFRcL0pIaFwvZkdyMU0zb1orZ0I2ZSJ9McKinsey gives us its perspective on trends in Medicare Advantage star ratings.
Read More
The last in a long series about specialty drug trends, including a look forward.
Read More
